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Abstract
Background: Two main types of receptors for gastrin and cholecystokinin (CCK) have been cloned and identified.
CCK1 (CCK-A) receptors are expressed in the pancreas, the gallbladder, and parts of the brain, while CCK2 (CCK-B/
gastrin) receptors (CCK2R) are expressed in gastric glands and in most of the brain. A splice variant of the CCK2R
designated CCKRi4sv (CCK-C), which is constitutively expressed in human pancreatic cancer cells, has also been
described. The purpose of the present investigation was to study CCK2R, CCK2i4svR, and gastrin mRNA expression
in human pancreatic adenocarcinoma on the assumption that co-expression of CCK2R and gastrin or constitutive
CCK2i4svR mRNA expression plays a pivotal role in the progression of pancreatic cancer.
Findings: PCR amplification using CCK2R specific primer-pairs, followed by ethidium-bromide stained agarose gel
electrophoresis revealed the expression of wild-type CCK2R mRNA in 12 of 17 biopsy specimens. A CCK2R intron 4
specific nested PCR assay revealed that CCK2i4svR mRNA was expressed in only one of the biopsy specimen. The
authenticity of PCR amplicons was confirmed by cloning of selected amplicons and DNA sequence analysis.
Moreover, we found that hitherto undescribed multiple forms of 3’-end variant CCK2R mRNAs with various
deletions in the retained intron 4 and exon 5, tentatively generating truncated proteins, were expressed in the
pancreatic adenocarcinomas.
Conclusion: Cloning and DNA sequencing of selected amplicons revealed that CCK2R and multiple CCK2i4svR-like
mRNAs are expressed in human pancreatic adenocarcinoma. The originally described CCK2i4svR mRNA was only
expressed in one of 17 tumours and appears to be rarely expressed in pancreatic adenocarcinoma. We report that
CCK2R- and gastrin mRNA co-expression may play a role in a portion, but not in all of these tumours, and that
aberrant splicing takes places in these tissues generating multiple forms of 3’-end variant CCK2R mRNAs.
Keywords: CCK2-receptor mRNA expressions CCK2i4sv splice variant mRNA, CCK2-receptor and gastrin mRNA co-
expression, amplified mRNA, human pancreatic adenocarcinoma
Background
Two main types of receptors for gastrin and cholecysto-
kinin (CCK) have been cloned and identified [1-4], the
CCK1-receptor (formerly named CCK-A receptor)
which is expressed in the pancreas, the gallbladder and
parts of the brain, whereas the CCK2-receptor (formerly
named CCK-B/gastrin receptors) is expressed in gastric
glands and in most of the brain [1-5]. Both types of
receptors are known to signal by coupling to G proteins
and to a have growth-stimulating effect [6,7]. CCK
receptor expression has been studied extensively in var-
ious tissues and cell-lines including normal and diseased
human pancreatic tissue. However, it has been sugges-
ted that CCK1- and CCK2-receptors are differently
expressed in normal human pancreas and pancreatic
cancer cells [5,8-14]. The significance of this remains
still unknown.
The relationship between CCK2-receptor (CCK2R)
mRNA, gastrin mRNA, and gastrin peptide expression
has been studied by several authors in the past
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[11,15-17]. In normal human pancreas low levels of gas-
trin mRNA were detected, but gastrin peptides were not
present. In contrast, pancreatic cancer cells and cell-
lines expressed high levels of CCK2 and gastrin mRNA
as well as gastrin peptides [15,17,18]. Gastrin has been
shown to stimulate the growth of human pancreatic
adenocarcinoma and pancreatic cancer cell-lines. Based
on these findings, it was suggested that human pancrea-
tic adenocarcinomas might be stimulated by an auto-
crine loop involving co-expression of CCK2R and
gastrin [7,17-19]. Apparently, an antisense oligonucleo-
tide directed against gastrin mRNA inhibited growth of
human pancreatic cancer cells up to 88% inhibition in a
dose dependent fashion, supporting the role of gastrin
as a growth regulatory peptide for human pancreatic
cancer [20]. In contrast, Ohlsson and co-workers
reported that gastrin had no growth promoting effect on
human pancreatic cancer cell-lines derived from pan-
creatic cancer biopsy specimens obtained at surgery
[21].
A CCK2R mRNA splice variant expressed in human
pancreatic cancer was originally reported by Smith and
co-workers [20,22]. These authors demonstrated that
the novel splice variant mRNA is expressed exclusively
in human pancreatic cancer and is not present in nor-
mal human pancreas. Based on their findings, the term
CCK-C or “cancer” receptor has been proposed [22].
Hellmich and co-workers [23] reported on the identifi-
cation and isolation of a novel splice variant of the
human CCK2R expressed in human colorectal cancers,
but not in normal colonic mucosa adjacent to the can-
cer. Molecular cloning and DNA sequencing revealed
that the novel splice variant mRNA was identical to the
CCK-C receptor and was designated CCK2i4svR (for
intron 4-containing splice variant receptor), and codes
for a CCK2R protein that contains 69 additional amino
acids. This protein was identical to the CCK-C receptor
[20,22]. Subsequent studies revealed that the novel
CCK2i4svR is constitutively expressed in an agonist-
independent manner by a Src tyrosine kinase-dependent
pathway [23-25]. Ding and co-workers [26] confirmed
the expression of the CCK2i4svR mRNA in pancreatic
cancer and no expression in normal pancreatic tissue.
Moreover, these authors reported that CCK2i4svR
mRNA expression is due to low levels of a U2 splicing
factor creating aberrant splicing in malignant cells [26].
The purpose of the present investigation was to study
the expression/co-expression of wild type CCK2R,
CCK2i4svR, and gastrin mRNA in human pancreatic
adenocarcinoma by means of RT-PCR and DNA
sequence analysis of selectively cloned PCR amplicons.
We report that CCK2R- and gastrin mRNA co-expres-
sion or constitutive CCK2i4svR mRNA expression
occurs only in a part of these tissues.
Methods
Tissue samples
Anonymous archival pancreatic tumour tissue samples
from 17 deceased patients with histopathological diag-
nosed pancreatic ductal adenocarcinoma were analysed.
The study was approved by the Regional Ethics commit-
tee in Linköping, Sweden (Dnr. M38-06). A tissue block
(minimum 5 × 5 × 5 mm) had been excised from the
primary tumour immediately after surgical resection (14
cases) or from extra-pancreatic tumour growths when
radical resection was not possible (peritoneal growth in
two cases and liver metastasis in one case). Care was
taken not to contaminate tissue samples with bile or
contents from the stomach or intestine. The samples
were stored at -80°C in RNA storage solution (Ambion,
Austin TX, USA) until RNA isolation.
Isolation of total RNA and poly(A)+ RNA
Total RNA was isolated from the tissue using the
RNeasy Midi kit (Qiagen, Hilden, Germany). A cube of
approximately 4 mm square was cut out from the tissue
sample and placed in 1.5 ml RTL buffer, containing b-
Mercaptoethanol. Three 3.2 mm Chrome-Steel beads
(BioSpec Products, Inc. Bartlesville OK, USA), pre-
washed in RTL buffer, were added to each tube. The tis-
sue samples were homogenized using the Mixer Mill
300 (Qiagen, Hilden, Germany) for 5 min at 30 Hz, the
tube racks were rotated 180° and then homogenized for
additional 5 min at 30 Hz. Normally, this was sufficient
for complete homogenisation of the tissue, but addi-
tional shaking was needed for some samples. After the
homogenisation, total RNA was isolated according to
the manufacturer’s instructions and eluted in two times
150 μl RNase-free water. Total RNA samples were con-
centrated using the RNeasy MinElute Cleanup kit (Qia-
gen, Hilden, Germany) and eluted in 20 μl RNase-free
water. Subsequently, total RNA was treated with a
TURBO DNase kit following the protocol (Ambion,
Austin TX, US). Poly(A)+ RNA (mRNA) was isolated
from total RNA using an automated BioRobot M48
workstation and the MagAttract Direct mRNA M48 kit
(Qiagen, Hilden, Germany) and concentrated as described
above. mRNA concentrations were measured using a Bio-
Photometer v. 1.32 (Eppendorf, Hamburg, Germany).
RNA amplification
100 ng of the poly(A)+ RNA was amplified twice in
independent reactions using the MessageAmp II aRNA
kit (Ambion, Austin TX, USA). The amplification is
based on the Eberwine protocol [27] where a T7-promo-
tor is incorporated into the ds-cDNA during reverse
transcription from the isolated mRNA. RNA is then
amplified using T7 RNA polymerase. The amplification
is linear and a possible bias introduced in amplified
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RNA is very low [28]. Before storage at -80°C, the
amplified antisense-RNA (aRNA) was quantified in tri-
plicate measurements, using a ND-1000 spectrophot-
ometer (Nanodrop Technologies, Wilmington DE, USA).
aRNA purity and ss-cDNA synthesis
The purity of RNA (absence of contaminating DNA)
was analysed by a commercially available b-actin control
PCR (Human b-actin Control Amplimer Set from BD-
Biosciences, Palo Alto CA, USA; Table 1) using PCR
condition No. 1 as specified (Table 2). The abundance
of b-actin pseudogenes in the human genome makes it
a suitable gene for control of DNA contamination [29].
The amplified aRNA contaminated with DNA was trea-
ted with the TURBO DNase kit (Ambion, Austin TX,
USA), following the rigorous protocol, and again vali-
dated by the b-actin control PCR.
Single stranded complementary DNA (ss-cDNA) was
synthesized using SuperScript III ss-cDNA synthesis sys-
tem (Invitrogen, Carlsbad CA, USA), hexamer primers
and approximately 100 ng poly(A)+ RNA template. The
ss-cDNA synthesis was repeated twice for each aRNA
sample, resulting in six cDNA pools from each biopsy.
The cDNA synthesis reaction was also validated using
the b-actin PCR.
PCR amplification
The expression of CCK2R, CCK2i4svR, and gastrin
mRNAs was assessed by PCR amplification of ss-cDNA.
Amplifications were carried out in a final reaction
volume of 25 μl using thin-walled reaction tubes, 1x
HotStarTaq Master Mix kit (Qiagen, Hilden, Germany),
and a PTC-100 Programmable Thermo Controller (MJ
Research; SDS Biosciences, Falkenberg, Sweden). Primer
sequences, expected amplicon sizes, and PCR amplifica-
tion conditions used are given in table 1 and table 2. A
schematic drawing of the CCK2R gene, CCK2R, and
CCK2i4svR mRNAs is shown, including the position of
the primers used in the present study (Figure 1 and 2).
To evaluate the expression of the gastrin gene, PCR
using the Gas1.SE (located in exon 2) and Gas1.AS
(located in exon 3) primer-pair (Table 1), and condi-
tion No. 1 (Table 2), was carried out. The expected
sizes of ss-cDNA or genomic DNA derived gastrin
amplicon are 256 bp and 386 bp (including intron 2),
respectively.
A nested PCR assay was used for validation of
expressed CCK2R mRNA variants. In the first amplifica-
tion step, primer 1 and 2 (hCCK-BR/I.SE and hCCK-BR
II.AS) located in exon 4 and 5 (Figure 2), and PCR
amplification condition No. 2 were used. Amplicons
were purified using the GFX PCR DNA gel band purifi-
cation kit (GE-Health Care, Uppsala, Sweden), followed
by a second PCR using 1 μl purified amplicon, primer 3
and 4 (CCKBRseq.se1 and CCKBR.as2), and PCR ampli-
fication condition No. 3.
To confirm the expression of CCK2i4svR mRNA, a
semi-nested PCR assays were carried out. Firstly, PCR
amplification was carried out using primer 5 (CCKBRwt.
SE) located in exon 3 and primer 6 (CCKBRwt.AS)
located in exon 5 (Figure 2) and PCR condition No. 4.
PCR amplicons were purified as described above. Geno-
mic DNA or ss-cDNA retaining intron 3 and 4 yields an
amplicon of 832 bp, ss-cDNA corresponding to
CCK2i4svR (retaining exon 4) an amplicon of 523 bp,
and ss-cDNA corresponding to the CCK2R an amplicon
of 317 bp. Semi-nested PCR was carried out using 1 μl
purified amplicon and primer 5 (CCKBRwt.SE) and pri-
mer 7 (CCKBi4svR.AS) located in intron 4 (Figure 2),
and PCR condition No. 2. Genomic DNA or ss-cDNA
retaining intron 3 yields an amplicon of 691 bp and ss-
cDNA corresponding to CCK2i4svR an amplicon of 383
bp (Table 1). Amplicons were visualised on an ethi-
dium-bromide stained 1.5% agarose gel. Genomic DNA
was included in all PCR amplification assays to visualise
differences in amplicon sizes compared to ss-cDNA
derived amplicons. No template controls were included
in all PCR assays.
Table 1 Primers used in PCR amplification.
Name Sequence, 5’ to 3’ direction Size (bp) Start position Reference
(1) hCCK-BR/I..SE 5’-GTGGCCTACGGGCTTATCTCTCGCGAGCTCTACTTA 358/565 709 [GenBank:AF239668]
(2) hCCK-BR/II.AS 5’-ACGTGTTGGCACTATAAACTGGCAACCAACACAG 1240
(3) CCKBRseq.SE1 5’-AGGGTCCGAAACCAAGGC 441/234 787
(4) CCK-BR.AS2 5’-AACGATCACCAGCAACATTCGC 1206
(5) CCK-BRwt.SE 5’-CGGACTACTCATGGTGCCCTAC 832/523/317 549
(6) CCK-BRwt.AS 5’-GCCAACCGCGCCAGTCTCAG 1052
(7) CCK-BRi4sv.AS 5’-CCATTTCCAGCTTCCTTCTCA 691/383 911
Gas1.SE 5’-CAGCAGCCAGATGCACCCTTAGGTACAG 386/256 6370 [GenBank:M15958.1]
Gas1.AS 5’-GGCTAGGCTCTGAAGCTTGGTTCTAGGATTGTTAG 6755
b-Actin.SE Human b-Actin Control Amplimer set 838 BD Biosciences, Palo Alto, CA. USA
b-Actin.AS
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Cloning of CCK2-receptor amplicons and DNA sequence
analysis
Amplicons were cloned using the TOPO-TA cloning kit
(Invitrogen, Carlsbad CA, USA). Positive clones were
selected and plasmid DNA was prepared by means of
multiple displacement amplification [30] using an Illus-
tra GenomiPhi V2 DNA amplification kit as recom-
mended by the manufacturer (GE-Healthcare, Uppsala,
Sweden). DNA sequence analysis was carried out with-
out further purification [31] by a customer DNA
sequencing service (Eurofins MWG Operon GmbH,
Martinsried, Germany). Generated DNA sequences were
aligned, edited, and compared with CCK2R [GenBank:
NM_176875.2] and CCK2i4svR [GenBank:AF441129]
which were retrieved from the NCBI Entrez Nucleotide
database [http://www.ncbi.nlm.nih.gov/nucleotide]. The




RNA and ss-cDNA synthesis
The amount of amplified mRNA obtained from each
biopsy ranged from ~2 to 80 μg with purity of A260/280
1.9 for most of the samples (ranging from 1.3-2.06). In
average, mRNA amplification yielded 6 μg aRNA from
60 ng mRNA input. The absence of human genomic
DNA after DNase treatment was confirmed by means of
b-actin amplification prior to the aRNA amplification
step (Figure 3A). Subsequently, aRNA (a maximum
volume of 8 μl, but not more than 500 ng) was used in
ss-cDNA synthesis, which was confirmed by b-actin
PCR amplification (Figure 3B).
Expression of CCK2-receptor and gastrin mRNAs
To determine the expression of CCK2R and gastrin
mRNAs, ss-cDNA derived from isolated human pan-
creatic adenocarcinoma biopsy specimens were analysed
by PCR using CCK2R and gastrin specific primers. Ethi-
dium-bromide stained agarose gel electrophoresis
revealed the presence of an approximately 250 bp ampli-
con corresponding to a wild-type (wt) CCK2R mRNA in
12 of 17 (71%) biopsy specimens (Figure 3C, lane 1, 2,
4-7, 10, 13-17). Furthermore, in 10 of these biopsies
(59%), both weak and strongly visible amplicons of
approximately 400-500 bp were present, indicating that
the CCK2R and CCK2i4svR-like mRNAs were co-
expressed (Figure 3C, lane 1, 2, 4-7, 13-16). In one
biopsy each, a single amplicon corresponding to
CCK2i4svR-like or CCK2R mRNA, respectively, was
present (Figure 3C, lane 8, 10). In four biopsy speci-
mens, no amplicons corresponding to CCK2R or
CCK2i4svR-like mRNAs were detected (Figure 3C, lane
3, 9, 11, 12). In 13 of 17 (76%) biopsy specimens, PCR
Table 2 PCR conditions.
PCR No. Initial denaturation Denaturation Annealing Extension Cycles Final extension
1 95°C, 15 min 95°C, 30 s 65°C, 30 s 72°C, 1 min 35 72°C, 10 min
2 95°C, 15 min 95°C, 30 s 65°C, 30 s 72°C, 1 min 30 72°C, 10 min
3 95°C, 15 min 95°C, 30 s 55°C, 30 s 72°C, 1 min 30 72°C, 10 min
4 95°C, 15 min 95°C, 30 s 52°C, 30 s 72°C, 1 min 30 72°C, 10 min
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5






Figure 1 Schematic drawing (not to scale) of the CCK2R gene exon/intron arrangement [3], the CCK2R mRNA (wt) [3], and CCK2i4svR
splice variant mRNA [23].
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amplicons corresponding to gastrin mRNAs were pre-
sent (Figure 3D, lane 2-10, 13-15, 17). CCK2R (wt) and
gastrin mRNAs were co-expressed in 10 of 17 (59%)
biopsy specimens (Figure 3C and 3D, lane 2, 4-7, 10,
13-15, 17), and in one case CCK2i4svR-like and gastrin
mRNA were co-expressed (Figure 3C and 3D, lane 8).
Similarly, CCK2R, -CCK2i4svR-like and gastrin mRNAs
were co-expressed in eight biopsy specimens (Figure 3C
and 3D, lane 2, 4-7, 13-15).
To confirm the expression of a CCK2i4svR-like
mRNA, a semi-nested PCR assay was carried out using
primers targeting exon 3 and 5, and intron 4 (Figure 2,
table 2). Surprisingly, only one of seven tentative
CCK2i4svR-like amplicons appears to correspond to the
originally described CCK2i4svR-mRNA (Figure 3E, lane
15). One amplicon revealed an unexpected size of
approximately 800 bp corresponding to a CCK2R
mRNA retaining intron 3 and 4 (Figure 3C, lane 7).
Cloning and DNA sequence analysis
DNA sequence analysis was carried out on selected and
cloned CCK2R amplicons. Sequences were aligned
in ClustalW and compared with CCK2R sequences
[GenBank:NM_176875.2] and CCK2i4svR [GenBank:
AF441129] (Figure 4). DNA sequence analysis revealed
that the two amplicons derived from sample No. 6 of





Figure 2 Schematic drawing (not to scale) of the CCK2R gene 3’-region corresponding DNA sequences of exon 3 to exon 5. Arrows
indicate the position of the CCK2R primers No. 1-7 described in Table 1.
Figure 3 Representative Ethidium-bromide stained agarose gel visualising PCR amplicons derived from 17 archival biopsy specimens
(lane 1 to 17). A) Quality control of total RNA (free of contaminating genomic DNA), and B) single-stranded cDNA by means of b-actin PCR
amplification after DNase treatment. C) Visualised amplicons from nested CCK2R, D) gastrin, and E) CCK2i4svR specific PCR assays as described in
methods. The position of the 500 bp size marker in each 100 bp ladder (lane M) is indicated. Black arrows in the left margin indicate the
position of a) amplicons derived from genomic DNA or cDNA retaining introns, b) wild-type CCK2 receptor and gastrin mRNA amplicons, and c)
CCK2i4svR splice variant amplicons derived from ss-cDNA. White arrows (lane 6, 10, and 17) indicate confirmed CCK2 receptor splice variants by
DNA sequencing. Stripped arrows indicate the position of the CCK2i4svR amplicon in sample No. 15. In all amplification assays human genomic
DNA (+) was included as control. (-) NTC (no DNA template added to the master mix).
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247 bp and 358 bp, respectively, (Figure 3C), correspond
to the CCK2R long form (Figure 4C) [22] and a new
CCK2i4R splice variant carrying a deletion of 83 bp in
the retained intron 4. In silico translation of the nucleo-
tide sequence generates a tentatively truncated CCK2R-
protein (Figure 4D). Semi-nested PCR revealed the
absence of a CCK2i4svR-specific amplicon (Figure 3E),
indicating that the cloned CCK2R sequences might be
attributed either to a new CCK2R variant lacking target
sequence for primer 7 (CCK-BRi4sv.AS, table 1), or to
contaminating genomic DNA.
The 180 bp amplicon derived from sample No. 10 repre-
sents another, hitherto undescribed CCK2R splice-variant
having a 162 bp deletion in the 3’-part of intron 4 and two
deletions in the 5’-part of exon 5. In silico-generated
amino acid sequence deviate from the originally described
CCK2i4svR sequence (Figure 4E). Sequence analysis of the
137 bp amplicon corresponding to the weak band visua-
lised in sample No. 17 (Figure 3C) revealed a 97 bp dele-
tion in exon 4, encoding a tentatively truncated CCK2R
variant protein (Figure 4F). The DNA sequences have




Gastrin is known to stimulate gastric acid secretion and
growth of the acid-producing mucosa [32,33]. It has also
been shown that gastrin stimulates pancreatic growth
[34,35]. If the current view of gastrin as a trophic regu-
lator of the pancreas is correct, the receptor for gastrin
(CCK2R) should be expected to be expressed in pan-
creas. By means of Northern blot and RT-PCR analysis,
we and others have shown that the CCK2R mRNA is
expressed in adult human pancreas [5,36,37]. Further-
more, it has been shown that CCK2R mRNA, gastrin
mRNA and its corresponding proteins are expressed in
human pancreatic adenocarcinoma [15,17]. The current
view is that co-expression of gastrin and CCK2R (wt)
regulates growth of human pancreatic cancer in an
autocrine fashion [17,18,20]. As judged from RT-PCR
analysis in the present study, CCK2R (wt) and gastrin
mRNA were both expressed in 10 of 17 biopsy speci-
mens. It was claimed in a previous study that nearly all
human pancreatic carcinomas studied expressed both
CCK2R (wt) and gastrin mRNA [17]. It could be argued
that the RT-PCR analysis used herein is not sensitive
enough to detect low levels of CCK2R- and gastrin
mRNA expression. To overcome this potential problem

























Figure 4 Schematic drawing (not to scale) of cloned and sequenced CCK2R variants. A) grey boxes correspond to amino acid sequences
(exon 4 and 5) of the wt CCK2R [GenBank:NM176875] and B) CCK2i4svR splice variant receptor (exon 4, intron 4, exon 5) [GenBank:AF441129]. C)
CCK2R splice variant consisting of exon 4, the first five N-terminal amino acids of intron 4, and one base truncation at the C-terminal end in
exon 5 [GenBank:DQ335648]. D) CCK2R splice variant consisting of exon 4, a deviating and truncated intron 4 (black boxes indicate that a frame-
shift mutation has occurred generating putative amino acids deviating from the wild-type sequences). [GenBank:DQ335649]. E) [GenBank:
DQ335650] and F) [GenBank:DQ335651] CCK2R splice variants with deviating amino acid sequences in intron 4 and exon 5 compared to CCK2R
(wt) and CCK2i4svR. Amino acid sequences deviating from previously reported CCK2R and CCK2i4svR sequences are indicated using the single
letter amino acid code. The positions of in frame stop codons yielding tentatively truncated CCK2 receptors in D) and F) are indicated by an
asterix.
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we used an initial mRNA amplification step which is
commonly used in chip-array based gene expression stu-
dies [27]. Thus, the present data suggest that co-expres-
sion may play a role in a portion but not in all of these
tumours.
Smith and co-workers showed that antisense oligonu-
cleotide to gastrin mRNA did not completely inhibit
growth of human pancreatic cancer [20]. This would
indicate that beside CCK2R/gastrin autocrine or para-
crine growth loops, hitherto unknown CCK2R or gastrin
induced pathways might be involved in stimulation of
pancreatic cancer growth, which could explain the
absence of co-expressed CCK2R (wt) and gastrin
mRNAs in our study. Constitutive expression of an
alternatively spliced CCK2i4svR mRNA activating intra-
cellular signal pathways has been described [22,23,38]
indicating that CCK2i4svR mRNA expression is a con-
tributing factor in human pancreatic cancer. However,
by means of RT-PCR analysis we found rather unex-
pectedly that only one of 17 pancreatic adenocarcinoma
biopsy specimens generates amplicons corresponding to
CCK2i4svR mRNA (Figure 3, lane 15).
On the other hand, molecular cloning and DNA
sequence analysis of selected CCK2i4svR amplicons as
described in the present study revealed a complex
CCK2R mRNA expression pattern in the human pan-
creatic adenocarcinomas. Beside CCK2R, CCK2R long
form, and CCK2i4svR mRNA, we present evidence for
the expression of three novel, hitherto undescribed
CCK2R variant mRNAs. It is tempting to speculate that
CCK2i4svR mRNA and these novel CCK2R mRNA var-
iants are generated by an aberrant splicing mechanism
as described by Ding and co-workers [26]. Using an in
vitro mini-gene expression, transcription, and splicing
system and the MIA PaCa-2 pancreatic cancer cell-line,
they were able to gain insight into the molecular
mechanism of missplicing of CCK2R pre-mRNA in
these cells. Re-engineering of the non-optimal 3’-splice
site in intron 4 of the CCK2R pre-mRNA, but not the
5’-splice site of this intron to the consensus sequence
markedly improved the splicing of the primary tran-
script in the MIA PaCa-2 pancreatic cancer cell-line.
Moreover, evidence was provided that the expression of
the U2AF35 splicing factor which specifically recognizes
the 3-end splice site, essential for correct pre-mRNA
splicing, is significantly lower in human pancreatic ade-
nocarcinoma and pancreatic cancer cell-lines than in
normal pancreatic tissue [26].
In this context, it is interesting to note that the three
novel CCK2R splice variants described in the present
study appear to be generated by missplicing at the 3’-
splice site in intron 4 (Figure 4D-F). In addition, two of
these novel CCK2R variants revealed alternative splicing
in exon 5, tentatively generating CCK2svR proteins with
an alternative carboxyl terminus (Figure 4E, F). CCK2R
internalisation and intracellular trafficking have been
shown to be influenced by a number of different struc-
tural determinants of the receptor, including the car-
boxyl terminus [39,40]. Thus, it is conceivable that an
altered carboxyl terminus generated by alternative spli-
cing of exon 5 may have an impact on internalisation
and intracellular trafficking of CCK2svR receptors. In
lack of experimental evidence, we can only speculate
that these novel 3’-end variant CCK2R mRNAs could be
translated into CCK2svR-like proteins with similar func-
tions in human pancreatic cancer growth as described
for the original CCK2i4sv receptor [22,23,38].
Aberrant alternative splicing of pre-mRNA, also
referred to as illegitimate or ectopic splicing [41], has
been found to be associated with various diseases,
including cancer. The discovery of cancer-specific, alter-
natively spliced isoforms has prompted interest in their
potential use as disease biomarkers, both at the mRNA
and protein level. Thus, it has been suggested that aber-
rant alternative splicing may provide a potential source
for new diagnostic and prognostic tools [42,43]. Deci-
phering the mechanisms underlying aberrant alternative
splicing of CCK2R pre-mRNA and a better understand-
ing of the biological function (if any) of its cognate pro-
teins may possibly lead to elucidation of human
pancreas transformation mechanisms and cancer
development.
Conclusion
By means of PCR amplification and cloning of selected
amplicons we show that aberrant splicing takes place in
pancreatic adenocarcinomas generating multiple forms
of 3’-end variant CCK2R mRNAs. Moreover, we find
that the originally described CCK2i4svR mRNA, which
is considered to be constitutively expressed in human
pancreatic adenocarcinoma, is rarely expressed in the
biopsy specimens studied.
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